Sickle Cell Disease/Advancing Cures
The 2019 Sickle Cell Disease/Advancing Cures competition is now open and accepting applications. Please see the Request for Applications document for information on how to apply. The deadline for submissions is May 31, 2019 at 3 p.m., ET.
The Doris Duke Sickle Cell Disease/Advancing Cures award provides grants to advance curative approaches for sickle cell disease, including gene modification and drug therapies to restore hemoglobin function.
Rationale & History
Research over the past five decades has resulted in treatments for sickle cell disease treatments that have decreased childhood mortality and improved patients’ disease management options for patients with sickle cell disease. However, further efforts are needed to develop approaches that aim to attack the disease at its core by safely and sustainably restoring hemoglobin function. The Sickle Cell Disease/Advancing Cures award was created to harness promising scientific advances toward restoring hemoglobin function and enable their development into clinically feasible therapies and ultimately practical use.
This award aims to support clinical research that will:
- Advance gene therapies for sickle cell disease into the clinic, including gene addition and genome editing.
- Build on globin regulatory mechanisms to restore red blood cell function.
- Advance bone marrow transplant approaches to minimize toxicities and improve outcomes.
In keeping with the wishes expressed in Doris Duke's will, experiments that use animals or primary tissues derived from animals will not be supported by this program.
Please email email@example.com with “2019 SCD/AC – [Last name]” as the subject line.
We advise that all inquiries be sent via email. No phone calls, please, as we cannot guarantee that all calls will receive an immediate response.
To receive announcements about future competitions for this and other programs, subscribe to our listserv here.